CoChat

Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus: A Subgroup Analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study

Athyros, Vasilios G., Papageorgiou, Athanasios A., Symeonidis, Athanasios N., Didangelos, Triandafillos P., Pehlivanidis, Anthimos N., Bouloukos, Vasilios I., Mikhailidis, Dimitrios P. · 2003 · Angiology

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

This is a prospective evaluation of the effect of structured care of dyslipidemia with atorvas tatin (strict implementation of guidelines) versus usual care (physician's standard of care) on morbidity and mortality of patients with coronary heart disease (CHD) and diabetes mellitus (DM). From 1600 consecutive CHD patients randomized to either form of care in the GREek Atorvastatin and CHD Evaluation Study (GREACE), 313 had DM: 161 in the structured care arm and 152 in the usual care arm. All patients were followed up for a mean of 3 years. In the structured care group, patients were treated with atorvastatin to achieve the National Cholesterol Education Program (NCEP) low-density lipoprotein cholesterol (LDL-C) treatment goal of < 2.6 mmol/L (100 mg/dL). Primary endpoints were all-cause and coronary mortality, coronary morbidity, and stroke. In the structured care group, 156 patients (97%) were taking atorvastatin (10-80 mg/day; mean, 23.7 mg/day) throughout the study; the NCEP LDL-C treatment goal was reached by 150 patients (93%). Only 17% (n = 26) of the usual care patients were on long-term hypolipidemic drug treatment and 4% (n = 6) reached the NCEP LDL-C treatment goal. During the study, 46 of 152 (30.3%) CHD patients with DM on usual care experienced a major vascular event or died versus 20 of 161 (12.5%) patients on structured care; relative risk reduction (RRR) 58%, p < 0.0001. RRR for all-cause mortality was 52%, p = 0.049; coronary mortality 62%, p = 0.042; coronary morbidity 59%, p < 0.002; and stroke 68%, p = 0.046. Event rate curves started deviating from the sixth treatment month and the RRR was almost 60% by the 12th month. RRRs remained at that level until the end of the study, when they became statistically significant. The cost/life-year gained with structured care was estimated at US $6200. In CHD patients with DM, structured care of dyslipidemia with atorvastatin to achieve the NCEP LDL-C treatment goal, reduces all-cause and coronary mortality, coronary morbidity, and stroke by more than one half within a 3-year period, in comparison to usual care. Clinical benefit is manifested as early as the sixth month of treatment.

Overview

Integrity signals

Registry

Crossref · 10.1177/000331970305400607

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Research works printed but not linked: 6

  1. American Diabetes Association, 2001, Diabetes Care, 24, S58
  2. Scandinavian Simvastatin Survival Study (4S) Group, 1994, Lancet, 344, 1383
  3. National Heart, Lung, and Blood Institute, 2000, Morbidity and Mortality: 2000 Chart Book
  4. 10.1001/archinte.1997.00440330039004 · doi:10.1001/archinte.1997.00440330039004 · Paper page
  5. 10.1185/0300799009117026 · DOI
  6. Youssef F., Angiology

Cited by

See all 85

Metadata

Authors
Athyros, V. G., Papageorgiou, A. A., Symeonidis, A. N., Didangelos, T. P., Pehlivanidis, A. N., Bouloukos, V. I., & Mikhailidis, D. P.
Affiliations
  • Aristotle University of Thessaloniki (GR)
  • Greek Society of General Practitioners, Thessaloniki, Greece.
  • Diabetes Center of North Greece, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece.
  • Atherosclerosis Unit and 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; Greek Society of General Practitioners, Thessaloniki, Greece; Diabetes Center of North Greece, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; and Department of Clinical Biochemistry, Royal Free Hospital, London.
Venue
Angiology
Published
2003-11
Volume
54
Issue
6
Pages
679-690
ISSN
  • 0003-3197 (ISSN-L)
  • 1940-1574
OpenAlex
W2004034044
Cited by
85
References
46
Citations by year
2023: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 2 · 2012: 4
FWCI
8.63
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Angiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords
coronary artery disease, diabetes mellitus, structured care, dyslipidemia, NCEP guidelines, all-cause mortality, coronary heart disease mortality, stroke, lipid-lowering therapy, cost-effectiveness, secondary prevention, cardiovascular risk reduction, cost per life year
MeSH terms
Atorvastatin, Anticholesteremic Agents, Coronary Disease, Diabetes Mellitus, Female, Heptanoic Acids, Humans, Male, Middle Aged, Prospective Studies, Pyrroles, Time Factors, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus: A Subgroup Analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. https://app.cochat.ai/papers/10.1177/000331970305400607
The paper
Athyros, V. G., Papageorgiou, A. A., Symeonidis, A. N., Didangelos, T. P., Pehlivanidis, A. N., Bouloukos, V. I., & Mikhailidis, D. P. (2003). Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus: A Subgroup Analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. Angiology. https://doi.org/10.1177/000331970305400607

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.